查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1698065

胰臟癌治疗与诊断市场－全球产业规模、份额、趋势、机会和预测，按类型细分，按最终用户、地区和竞争情况，2020 年至 2030 年预测

Pancreatic Cancer Therapeutics & Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type, By End-User By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球胰臟癌治疗和诊断市场价值为 46 亿美元，预计在预测期内将实现强劲成长，到 2030 年的复合年增长率为 7.50%。全球胰臟癌治疗和诊断市场是医疗保健行业一个充满活力且不断发展的领域，其驱动力是对抗最致命的癌症之一的迫切需求。

市场概览
预测期 2026-2030
2024 年市场规模 46亿美元
2030年市场规模 71.2亿美元
2025-2030 年复合年增长率 7.50％
成长最快的领域 治疗
最大的市场 北美洲

胰臟癌是一种相对罕见的癌症，占所有癌症病例的一小部分。然而，它是最致命的癌症之一，存活率很低。胰臟癌的发生率因地区而异，有些地区的发生率高于其他地区。风险因素包括年龄、家族史、吸烟、肥胖和某些基因突变。

主要市场驱动因素

胰臟癌发生率上升

主要市场挑战

治疗费用高昂

主要市场趋势

个人化医疗的进展

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第四章：顾客之声

第五章：胰臟癌治疗与诊断市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按类型（治疗 {标靶治疗、化疗、手术、其他}、诊断 {影像、活检、内视镜超音波、其他}）
    • 按最终使用者（医院和诊所、行动中心、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美胰臟癌治疗与诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第 7 章：欧洲胰臟癌治疗与诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第八章：亚太地区胰臟癌治疗与诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：南美胰臟癌治疗与诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲胰臟癌治疗和诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章：全球胰臟癌治疗与诊断市场：SWOT 分析

第 14 章：竞争格局

  • Myriad Genetics Inc.
  • Pfizer Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Amgen Inc.
  • Viatris Inc.
  • Boston Scientific Corporation
  • FUJIFILM Holdings Corporation
  • Canon Inc. (canon Medical Systems Corporation)
  • Rafael Holdings Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 17509

Global Pancreatic Cancer Therapeutics & Diagnostics Market was valued at USD 4.60 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 7.50% through 2030. The Global Pancreatic Cancer Therapeutics & Diagnostics Market is a dynamic and evolving sector of the healthcare industry, driven by the urgent need to combat one of the deadliest forms of cancer.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.60 Billion
Market Size 2030USD 7.12 Billion
CAGR 2025-20307.50%
Fastest Growing SegmentTreatment
Largest MarketNorth America

Pancreatic cancer is a relatively rare cancer, accounting for a small percentage of all cancer cases. However, it is one of the most lethal forms of cancer, with a low survival rate. The incidence of pancreatic cancer varies by region, with some areas experiencing higher rates than others. Risk factors include age, family history, smoking, obesity, and certain genetic mutations.

Key Market Drivers

Rising Incidence of Pancreatic Cancer

The increasing incidence of pancreatic cancer is a major driving force behind the expansion of the Global Pancreatic Cancer Therapeutics & Diagnostics Market. Pancreatic cancer remains one of the most lethal malignancies, posing a significant challenge to global healthcare systems. In 2020, approximately 500,000 new cases were reported worldwide, with 470,000 fatalities, underscoring the disease's high mortality rate. The global incidence rate stood at 4.9 cases per 100,000 people, while the mortality rate reached 4.5 per 100,000, highlighting the urgent need for more effective diagnostic and therapeutic interventions. This trend is influencing the demand for advanced treatment options, early diagnostic solutions, and improved healthcare infrastructure. Pancreatic cancer is among the most aggressive malignancies, with a high mortality rate. Due to late-stage diagnoses and limited treatment options, the survival rate remains low. The five-year survival rate for pancreatic cancer varies significantly based on the stage at diagnosis. For patients diagnosed at an early, operable stage, the survival rate reaches 20%. However, when considering all cases-including advanced, inoperable stages-the overall five-year survival rate drops to just 5%. The rising number of diagnosed cases worldwide is directly fueling the demand for innovative therapeutic solutions, including chemotherapy, immunotherapy, targeted therapy, and personalized medicine.

Key Market Challenges

High Treatment Costs

Pancreatic cancer treatment can be prohibitively expensive. The disease often necessitates aggressive interventions, including surgery, chemotherapy, radiation therapy, and personalized targeted therapies. These treatments not only involve substantial direct medical costs but also indirect costs related to hospitalization, supportive care, and managing side effects. Additionally, the complexity of pancreatic cancer cases often requires specialized healthcare providers and facilities, further driving up costs.

High treatment costs pose financial burdens on patients, healthcare systems, and insurers. This can limit patient access to advanced therapies and diagnostics, impacting market growth. Moreover, it can lead to delays in seeking treatment and influence treatment choices based on cost considerations rather than optimal clinical outcomes.

Key Market Trends

Advancements in Personalized Medicine

Personalized medicine is a significant trend in the treatment of pancreatic cancer. This approach tailors treatment plans based on an individual patient's genetic makeup, tumor characteristics, and other factors. Advancements in genomics and molecular profiling technologies have made it possible to identify specific mutations and biomarkers associated with pancreatic cancer. This trend is driven by the need for more effective and targeted therapies, as standard treatments have shown limited success in improving survival rates for pancreatic cancer patients.

The adoption of personalized medicine is expanding the range of therapeutic options available in the market. Pharmaceutical companies are developing targeted therapies that address specific genetic mutations, offering new hope for patients. Diagnostic tools that enable genetic profiling and guide treatment decisions are also in high demand. This trend is expected to drive market growth as more personalized treatment approaches become available.

Key Market Players

  • Myriad Genetics Inc.
  • Pfizer Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Amgen Inc.
  • Viatris Inc.
  • Boston Scientific Corporation
  • FUJIFILM Holdings Corporation
  • Canon Inc. (canon Medical Systems Corporation)
  • Rafael Holdings Inc

Report Scope:

In this report, the Global Pancreatic Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pancreatic Cancer Therapeutics & Diagnostics Market, By Type:

  • Treatment
  • Diagnostics

Pancreatic Cancer Therapeutics & Diagnostics Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Centers
  • Others

Pancreatic Cancer Therapeutics & Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Pancreatic Cancer Therapeutics & Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Treatment {Targeted Therapies, Chemotherapy, Surgery, Other}, Diagnostics {Imaging, Biopsy, Endoscopic Ultrasound, Other})
    • 5.2.2. By End-User (Hospital & Clinic, Ambulatory Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End User

7. Europe Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End User
    • 7.3.4. France Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End User

8. Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End User

9. South America Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User

10. Middle East and Africa Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Pancreatic Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Myriad Genetics Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Pfizer Inc.
  • 14.3. Novartis AG
  • 14.4. Bristol-Myers Squibb Company
  • 14.5. AstraZeneca PLC
  • 14.6. Amgen Inc.
  • 14.7. Viatris Inc.
  • 14.8. Boston Scientific Corporation
  • 14.9. FUJIFILM Holdings Corporation
  • 14.10.Canon Inc. (canon Medical Systems Corporation)
  • 14.11.Rafael Holdings Inc.

15. Strategic Recommendations

16. About Us & Disclaimer